[ { "@id": "http://purl.org/np/RAza6OegZBspU4MyGfe_LuRyxrhfN03TKYVHfssHHuEYE#Head", "@graph": [ { "@id": "http://purl.org/np/RAza6OegZBspU4MyGfe_LuRyxrhfN03TKYVHfssHHuEYE", "http://www.nanopub.org/nschema#hasAssertion": [ { "@id": "http://purl.org/np/RAza6OegZBspU4MyGfe_LuRyxrhfN03TKYVHfssHHuEYE#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance": [ { "@id": "http://purl.org/np/RAza6OegZBspU4MyGfe_LuRyxrhfN03TKYVHfssHHuEYE#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo": [ { "@id": "http://purl.org/np/RAza6OegZBspU4MyGfe_LuRyxrhfN03TKYVHfssHHuEYE#pubInfo" } ], "@type": [ "http://www.nanopub.org/nschema#Nanopublication" ] } ] }, { "@id": "http://purl.org/np/RAza6OegZBspU4MyGfe_LuRyxrhfN03TKYVHfssHHuEYE#provenance", "@graph": [ { "@id": "http://purl.org/np/RAza6OegZBspU4MyGfe_LuRyxrhfN03TKYVHfssHHuEYE#assertion", "http://www.w3.org/ns/prov#wasAttributedTo": [ { "@id": "https://orcid.org/0000-0002-7641-6446" } ] } ] }, { "@id": "http://purl.org/np/RAza6OegZBspU4MyGfe_LuRyxrhfN03TKYVHfssHHuEYE#pubInfo", "@graph": [ { "@id": "http://purl.org/np/RAza6OegZBspU4MyGfe_LuRyxrhfN03TKYVHfssHHuEYE#sig", "http://purl.org/nanopub/x/hasAlgorithm": [ { "@value": "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey": [ { "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature": [ { "@value": "IsaYQcqG4/ByvsmkRNQkrMu0GMoGb4jVZthrPRXpM5cR9OM/c6UQsLAFxgyvSCt4etAS1FhW/vR2aRMRbDekxhY7TSTcm+TqJnN7dd/1fa17MeNABon/Nfeb5yNVxNL7TZ1jBNoOuZ+//nXHoyIe+E4OI/gAvJ8sNgrVIxOywHc=" } ], "http://purl.org/nanopub/x/hasSignatureTarget": [ { "@id": "http://purl.org/np/RAza6OegZBspU4MyGfe_LuRyxrhfN03TKYVHfssHHuEYE" } ] }, { "@id": "http://purl.org/np/RAza6OegZBspU4MyGfe_LuRyxrhfN03TKYVHfssHHuEYE", "http://www.w3.org/ns/prov#generatedAtTime": [ { "@value": "2022-09-16T11:53:42.407140", "@type": "http://www.w3.org/2001/XMLSchema#dateTime" } ], "http://www.w3.org/ns/prov#wasAttributedTo": [ { "@id": "https://orcid.org/0000-0002-1501-1082" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [ { "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY" } ] }, { "@id": "https://w3id.org/biolink/vocab/", "http://purl.org/pav/version": [ { "@value": "2.3.0" } ] } ] }, { "@id": "http://purl.org/np/RAza6OegZBspU4MyGfe_LuRyxrhfN03TKYVHfssHHuEYE#assertion", "@graph": [ { "@id": "http://identifiers.org/drugbank/DB00363", "@type": [ "https://w3id.org/biolink/vocab/Drug" ], "http://www.w3.org/2000/01/rdf-schema#label": [ { "@value": "clozapine" } ], "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Drug" } ] }, { "@id": "http://purl.obolibrary.org/obo/MONDO_0008114", "@type": [ "https://w3id.org/biolink/vocab/Disease" ], "http://www.w3.org/2000/01/rdf-schema#label": [ { "@value": "obsessive-compulsive disorder" } ], "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id": "http://purl.org/np/RAza6OegZBspU4MyGfe_LuRyxrhfN03TKYVHfssHHuEYE#association", "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [ { "@id": "http://purl.obolibrary.org/obo/MONDO_0008114" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [ { "@id": "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [ { "@id": "http://identifiers.org/drugbank/DB00363" } ], "@type": [ "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation" ], "http://www.w3.org/2000/01/rdf-schema#label": [ { "@value": "Clozapine is not recommended for OCD due to poor evidence of efficacy [170]. In addition, several case reports and clinical studies support the association of clozapine with worsening or onset of obsessive-compulsive symptoms in patients with a psychotic disorder [171-176]. At least 20% of individuals treated with clozapine (and other antiserotonergic antipsychotics) would experience worsening or emergence of obsessive-compulsive symptoms [177], which are dose-related [178] and generally reversible upon discontinuation of clozapine treatment and switch to a different antipsychotic [179]" } ], "https://w3id.org/biolink/vocab/aggregator_knowledge_source": [ { "@id": "https://w3id.org/biolink/infores/knowledge-collaboratory" } ], "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation" } ], "https://w3id.org/biolink/vocab/has_population_context": [ { "@id": "http://purl.org/np/RAza6OegZBspU4MyGfe_LuRyxrhfN03TKYVHfssHHuEYE#context" } ], "https://w3id.org/biolink/vocab/publications": [ { "@id": "http://www.ncbi.nlm.nih.gov/pubmed/30101713" } ], "https://w3id.org/biolink/vocab/relation": [ { "@id": "http://purl.obolibrary.org/obo/NCIT_C94303" } ] }, { "@id": "http://purl.org/np/RAza6OegZBspU4MyGfe_LuRyxrhfN03TKYVHfssHHuEYE#context", "@type": [ "https://w3id.org/biolink/vocab/Cohort" ], "http://www.w3.org/2000/01/rdf-schema#label": [ { "@value": "adults" } ], "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Cohort" } ] } ] } ]